Purpose
There is a lack of agreement regarding the types of lesions and clinical conditions that should be included in the term “geographic atrophy”. Varied and conflicting views prevail throughout the literature and are currently used by retinal experts and other health care professionals.
Methods
We reviewed the nominal definition of the term “geographic atrophy” and conducted a search of the ophthalmological literature focusing on preceding terminologies as well as the first citations of the term “geographic atrophy” secondary to age-related macular degeneration (AMD).
Results
According to the nominal definition, the term “geography” stands for a detailed description of the surface features of a specific region, indicating its relative position. However, it does not necessarily imply that the borders of the region must be sharply demarcated or related to any anatomical structures. The term “geographical areas of atrophy” was initially cited in the 1960s in the ophthalmological literature in the context of uveitic eye disease and shortly thereafter also for the description of variants of “senile macular degeneration”. However, no direct explanation could be found in the literature as to why the terms “geographical” and “geographic” were chosen. Presumably the terms were used as the atrophic regions resembled the map of a continent or well-defined country borders on thematic geographical maps. With the evolution of the terminology, the commonly used adjunct “of the retinal pigment epithelium” was frequently omitted and solely the term “geographic atrophy” prevailed for the non-exudative late-stage of AMD itself. Along with the quantification of atrophic areas, based on different imaging modalities and the use of both manual and semi-automated approaches, various and inconsistent definitions for the minimal lesion diameter or size of atrophic lesions have also emerged.
Conclusions
Reconsideration of the application of the term “geographic atrophy” in the context of AMD appears to be prudent given ongoing advances in multi-modal retinal imaging technology with identification of various phenotypic characteristics, and the observation of atrophy development in eyes under anti-angiogenic therapy.